



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

February 18, 2020

Via E-mail  
Robert Gagnon  
Chief Business and Financial Officer  
Verastem, Inc.  
117 Kendrick Street, Suite 500  
Needham, MA 02494

**Re: Verastem, Inc.**  
**Form 10-Q for the quarterly period ended September 30, 2019**  
**Exhibit No. 10.1 - License and Collaboration Agreement, dated July 25, 2019,**  
**between Verastem, Inc. and Sanofi**  
**Filed October 30, 2019**  
**File No. 001-35403**

Dear Mr. Gagnon:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance